1. Home
  2. BTGO vs TBPH Comparison

BTGO vs TBPH Comparison

Compare BTGO & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTGO

BitGo Holdings Inc. Class A Common Stock

N/A

Current Price

$10.37

Market Cap

961.8M

Sector

Finance

ML Signal

N/A

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.70

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTGO
TBPH
Founded
2013
2013
Country
United States
United States
Employees
603
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
961.8M
824.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
BTGO
TBPH
Price
$10.37
$16.70
Analyst Decision
Strong Buy
Buy
Analyst Count
9
6
Target Price
$14.83
$18.40
AVG Volume (30 Days)
511.3K
473.9K
Earning Date
05-26-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
279.13
EPS
N/A
2.06
Revenue
N/A
$15,386,000.00
Revenue This Year
N/A
$1.04
Revenue Next Year
$34.97
N/A
P/E Ratio
$10.81
$8.08
Revenue Growth
N/A
N/A
52 Week Low
$7.25
$8.33
52 Week High
$15.30
$21.03

Technical Indicators

Market Signals
Indicator
BTGO
TBPH
Relative Strength Index (RSI) 57.93 60.30
Support Level $9.82 $13.41
Resistance Level $10.59 $19.04
Average True Range (ATR) 0.74 0.51
MACD 0.32 0.20
Stochastic Oscillator 91.30 87.99

Price Performance

Historical Comparison
BTGO
TBPH

About BTGO BitGo Holdings Inc. Class A Common Stock

BitGo Holdings Inc provides various offerings to its clients including multi-signature blockchain wallet solutions allowing for secure storage, trade settlement, staking solutions, and lending of digital assets. The Company also provides professional services to develop smart contracts. Its clients range from crypto-native companies that use its self-custody wallet technology to traditional financial services firms that leverage its licensed custody, staking and trading capabilities within their own products and services.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: